Impact of Lipodystrophy on Metabolic Syndrome in HIV Patients
Author Information
Author(s): Paula Freitas, Davide Carvalho, Selma Souto, Ana Cristina Santos, Sandra Xerinda, Rui Marques, Esteban Martinez, António Sarmento, José Luís Medina
Primary Institution: Centro Hospitalar São João, E.P.E., University of Porto Medical School
Hypothesis
Does clinical lipodystrophy affect the prevalence of metabolic syndrome in HIV-infected patients?
Conclusion
The prevalence of metabolic syndrome was high among HIV-infected patients, which may contribute to their increased cardiovascular disease risk.
Supporting Evidence
- 58.7% of patients had clinical lipodystrophy.
- 52.2% prevalence of metabolic syndrome using ATPIII criteria.
- 43.2% prevalence of metabolic syndrome using IDF criteria.
- Patients with clinical lipodystrophy had a higher risk of coronary heart disease.
Takeaway
This study looked at HIV patients and found that many of them had a condition called metabolic syndrome, which can make their hearts sick.
Methodology
A cross-sectional study evaluating 345 HIV-infected patients on cART using two definitions of metabolic syndrome.
Potential Biases
Potential selection bias due to referral from infectious disease specialists for metabolic disorders.
Limitations
The study did not exclude patients with pre-existing diabetes or hypertension, and selection bias may have influenced the results.
Participant Demographics
345 non-institutionalized, HIV-infected Caucasian adults (239 males), average age 40 years.
Statistical Information
P-Value
p = 0.738 for ATPIII, p = 0.379 for IDF
Confidence Interval
95% CI for various odds ratios reported
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website